Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post‐brain metastases survival
BACKGROUND: Melanoma patients who develop brain metastases (B‐Met) have limited survival and are excluded from most clinical trials. In the current study, the authors attempted to identify primary tumor characteristics and clinical features predictive of B‐Met development and post‐B–Met survival. ME...
Saved in:
Published in: | Cancer Vol. 117; no. 8; pp. 1711 - 1720 |
---|---|
Main Authors: | , , , , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
Hoboken
Wiley Subscription Services, Inc., A Wiley Company
15-04-2011
Wiley-Blackwell |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | BACKGROUND:
Melanoma patients who develop brain metastases (B‐Met) have limited survival and are excluded from most clinical trials. In the current study, the authors attempted to identify primary tumor characteristics and clinical features predictive of B‐Met development and post‐B–Met survival.
METHODS:
A prospectively accrued cohort of 900 melanoma patients was studied to identify clinicopathologic features of primary melanoma (eg, thickness, ulceration, mitotic index, and lymphovascular invasion) that are predictive of B‐Met development and survival after a diagnosis of B‐Met. Associations between clinical variables present at the time of B‐Met diagnosis (eg, extracranial metastases, B‐Met location, and the presence of neurological symptoms) and post‐B–Met survival were also assessed. Univariate associations were analyzed using Kaplan‐Meier survival analysis, and the effect of independent predictors was assessed using multivariate Cox proportional hazards regression analysis.
RESULTS:
Of the 900 melanoma patients studied, 89 (10%) developed B‐Met. Ulceration and site of the primary tumor on the head and neck were found to be independent predictors of B‐Met development on multivariate analysis (P = .001 and P = .003, respectively). Clinical variables found to be predictive of post‐B–Met survival on multivariate analysis included the presence of neurological symptoms (P = .008) and extracranial metastases (P = .04). Ulceration was the only primary tumor characteristic that remained a significant predictor of post‐B–Met survival on multivariate analysis (P = .04).
CONCLUSIONS:
Primary tumor ulceration was found to be the strongest predictor of B‐Met development and remained an independent predictor of decreased post‐B–Met survival in a multivariate analysis inclusive of primary tumor characteristics and clinical variables. The results of the current study suggest that patients with ulcerated primary tumors should be prospectively studied to determine whether heightened surveillance for B‐Met can improve clinical outcome. Cancer 2011. © 2010 American Cancer Society.
Ulceration of the primary tumor was found to be the strongest predictor of melanoma brain metastases (B‐Met) development and remained an independent predictor of decreased post‐B–Met survival in a multivariate analysis inclusive of primary tumor characteristics and clinical variables. The results of the current study suggest that patients with ulcerated primary tumors should be prospectively studied to determine whether heightened surveillance for B‐Met can improve clinical outcome. |
---|---|
AbstractList | Melanoma patients who develop brain metastases (B-Met) have limited survival and are excluded from most clinical trials. In the current study, the authors attempted to identify primary tumor characteristics and clinical features predictive of B-Met development and post-B-Met survival.
A prospectively accrued cohort of 900 melanoma patients was studied to identify clinicopathologic features of primary melanoma (eg, thickness, ulceration, mitotic index, and lymphovascular invasion) that are predictive of B-Met development and survival after a diagnosis of B-Met. Associations between clinical variables present at the time of B-Met diagnosis (eg, extracranial metastases, B-Met location, and the presence of neurological symptoms) and post-B-Met survival were also assessed. Univariate associations were analyzed using Kaplan-Meier survival analysis, and the effect of independent predictors was assessed using multivariate Cox proportional hazards regression analysis.
Of the 900 melanoma patients studied, 89 (10%) developed B-Met. Ulceration and site of the primary tumor on the head and neck were found to be independent predictors of B-Met development on multivariate analysis (P = .001 and P = .003, respectively). Clinical variables found to be predictive of post-B-Met survival on multivariate analysis included the presence of neurological symptoms (P = .008) and extracranial metastases (P = .04). Ulceration was the only primary tumor characteristic that remained a significant predictor of post-B-Met survival on multivariate analysis (P = .04).
Primary tumor ulceration was found to be the strongest predictor of B-Met development and remained an independent predictor of decreased post-B-Met survival in a multivariate analysis inclusive of primary tumor characteristics and clinical variables. The results of the current study suggest that patients with ulcerated primary tumors should be prospectively studied to determine whether heightened surveillance for B-Met can improve clinical outcome. BACKGROUND: Melanoma patients who develop brain metastases (B-Met) have limited survival and are excluded from most clinical trials. In the current study, the authors attempted to identify primary tumor characteristics and clinical features predictive of B-Met development and post-B-Met survival. METHODS: A prospectively accrued cohort of 900 melanoma patients was studied to identify clinicopathologic features of primary melanoma (eg, thickness, ulceration, mitotic index, and lymphovascular invasion) that are predictive of B-Met development and survival after a diagnosis of B-Met. Associations between clinical variables present at the time of B-Met diagnosis (eg, extracranial metastases, B-Met location, and the presence of neurological symptoms) and post-B-Met survival were also assessed. Univariate associations were analyzed using Kaplan-Meier survival analysis, and the effect of independent predictors was assessed using multivariate Cox proportional hazards regression analysis. RESULTS: Of the 900 melanoma patients studied, 89 (10%) developed B-Met. Ulceration and site of the primary tumor on the head and neck were found to be independent predictors of B-Met development on multivariate analysis (P = .001 and P = .003, respectively). Clinical variables found to be predictive of post-B-Met survival on multivariate analysis included the presence of neurological symptoms (P = .008) and extracranial metastases (P = .04). Ulceration was the only primary tumor characteristic that remained a significant predictor of post-B-Met survival on multivariate analysis (P = .04). CONCLUSIONS: Primary tumor ulceration was found to be the strongest predictor of B-Met development and remained an independent predictor of decreased post-B-Met survival in a multivariate analysis inclusive of primary tumor characteristics and clinical variables. The results of the current study suggest that patients with ulcerated primary tumors should be prospectively studied to determine whether heightened surveillance for B-Met can improve clinical outcome. Cancer 2011. [copy 2010 American Cancer Society. BACKGROUNDMelanoma patients who develop brain metastases (B-Met) have limited survival and are excluded from most clinical trials. In the current study, the authors attempted to identify primary tumor characteristics and clinical features predictive of B-Met development and post-B-Met survival. METHODSA prospectively accrued cohort of 900 melanoma patients was studied to identify clinicopathologic features of primary melanoma (eg, thickness, ulceration, mitotic index, and lymphovascular invasion) that are predictive of B-Met development and survival after a diagnosis of B-Met. Associations between clinical variables present at the time of B-Met diagnosis (eg, extracranial metastases, B-Met location, and the presence of neurological symptoms) and post-B-Met survival were also assessed. Univariate associations were analyzed using Kaplan-Meier survival analysis, and the effect of independent predictors was assessed using multivariate Cox proportional hazards regression analysis. RESULTSOf the 900 melanoma patients studied, 89 (10%) developed B-Met. Ulceration and site of the primary tumor on the head and neck were found to be independent predictors of B-Met development on multivariate analysis (P = .001 and P = .003, respectively). Clinical variables found to be predictive of post-B-Met survival on multivariate analysis included the presence of neurological symptoms (P = .008) and extracranial metastases (P = .04). Ulceration was the only primary tumor characteristic that remained a significant predictor of post-B-Met survival on multivariate analysis (P = .04). CONCLUSIONSPrimary tumor ulceration was found to be the strongest predictor of B-Met development and remained an independent predictor of decreased post-B-Met survival in a multivariate analysis inclusive of primary tumor characteristics and clinical variables. The results of the current study suggest that patients with ulcerated primary tumors should be prospectively studied to determine whether heightened surveillance for B-Met can improve clinical outcome. BACKGROUND: Melanoma patients who develop brain metastases (B‐Met) have limited survival and are excluded from most clinical trials. In the current study, the authors attempted to identify primary tumor characteristics and clinical features predictive of B‐Met development and post‐B–Met survival. METHODS: A prospectively accrued cohort of 900 melanoma patients was studied to identify clinicopathologic features of primary melanoma (eg, thickness, ulceration, mitotic index, and lymphovascular invasion) that are predictive of B‐Met development and survival after a diagnosis of B‐Met. Associations between clinical variables present at the time of B‐Met diagnosis (eg, extracranial metastases, B‐Met location, and the presence of neurological symptoms) and post‐B–Met survival were also assessed. Univariate associations were analyzed using Kaplan‐Meier survival analysis, and the effect of independent predictors was assessed using multivariate Cox proportional hazards regression analysis. RESULTS: Of the 900 melanoma patients studied, 89 (10%) developed B‐Met. Ulceration and site of the primary tumor on the head and neck were found to be independent predictors of B‐Met development on multivariate analysis (P = .001 and P = .003, respectively). Clinical variables found to be predictive of post‐B–Met survival on multivariate analysis included the presence of neurological symptoms (P = .008) and extracranial metastases (P = .04). Ulceration was the only primary tumor characteristic that remained a significant predictor of post‐B–Met survival on multivariate analysis (P = .04). CONCLUSIONS: Primary tumor ulceration was found to be the strongest predictor of B‐Met development and remained an independent predictor of decreased post‐B–Met survival in a multivariate analysis inclusive of primary tumor characteristics and clinical variables. The results of the current study suggest that patients with ulcerated primary tumors should be prospectively studied to determine whether heightened surveillance for B‐Met can improve clinical outcome. Cancer 2011. © 2010 American Cancer Society. Ulceration of the primary tumor was found to be the strongest predictor of melanoma brain metastases (B‐Met) development and remained an independent predictor of decreased post‐B–Met survival in a multivariate analysis inclusive of primary tumor characteristics and clinical variables. The results of the current study suggest that patients with ulcerated primary tumors should be prospectively studied to determine whether heightened surveillance for B‐Met can improve clinical outcome. |
Author | Hernando, Eva Pavlick, Anna Geraghty, Laurel N. Rose, Amy E. Mazumdar, Madhu Osman, Iman Darvishian, Farbod Zakrzewski, Jan Christos, Paul J. Shapiro, Richard Berman, Russell Polsky, David |
Author_xml | – sequence: 1 givenname: Jan surname: Zakrzewski fullname: Zakrzewski, Jan – sequence: 2 givenname: Laurel N. surname: Geraghty fullname: Geraghty, Laurel N. – sequence: 3 givenname: Amy E. surname: Rose fullname: Rose, Amy E. – sequence: 4 givenname: Paul J. surname: Christos fullname: Christos, Paul J. – sequence: 5 givenname: Madhu surname: Mazumdar fullname: Mazumdar, Madhu – sequence: 6 givenname: David surname: Polsky fullname: Polsky, David – sequence: 7 givenname: Richard surname: Shapiro fullname: Shapiro, Richard – sequence: 8 givenname: Russell surname: Berman fullname: Berman, Russell – sequence: 9 givenname: Farbod surname: Darvishian fullname: Darvishian, Farbod – sequence: 10 givenname: Eva surname: Hernando fullname: Hernando, Eva – sequence: 11 givenname: Anna surname: Pavlick fullname: Pavlick, Anna – sequence: 12 givenname: Iman surname: Osman fullname: Osman, Iman email: iman.osman@nyumc.org |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24042181$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/21472718$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc-KFDEQxoOsuLOrFx9AchFF6DVJpzuZ49L4DxYFUfDW1CQVNpJOj0l3y958hD3sE_okZnZm9SAspAiV-vFVpb4TchTHiIQ85eyMMyZem2jSmWhaWT8gK87WqmJciiOyYozpqpH1t2NykvP3kirR1I_IseBSCcX1itx0wUdvINAFkodNwEwhWrpNfoB0Rad5GBM1l5DATJh8nrzJpYrWm8kvSEdHp0ukFhcM43bAOO2eBgwQxwHoJoGPJZ0gl3MnPubp96_r_2p5TotfIDwmDx2EjE8O9yn5-vbNl-59dfHp3Yfu_KIyUqi6soq3zCmn19y6GtY1422tuGRSNgJBWuusc1YaqRGxlSgbZZwBobVaG9D1KXmx192m8ceMeeoHnw2GMjuOc-51ywWTTPNCvryX5KLWJQpc0Fd71KQx54SuP-yy56zf-dXv_Opv_Srws4PuvBnQ_kXvDCrA8wMAubjkEkTj8z-ufFbw2wH5nvvpA17d07LvPnaf983_AOKhs6Q |
CODEN | CANCAR |
CitedBy_id | crossref_primary_10_1038_s41598_019_40570_1 crossref_primary_10_1245_s10434_014_3829_9 crossref_primary_10_1007_s10585_013_9611_8 crossref_primary_10_1097_PPO_0b013e31824b2890 crossref_primary_10_3171_2014_9_JNS141425 crossref_primary_10_3390_biom10101357 crossref_primary_10_1002_cncr_30946 crossref_primary_10_1007_s12032_013_0466_2 crossref_primary_10_1093_noajnl_vdz017 crossref_primary_10_3390_cells11121873 crossref_primary_10_3390_cancers16112134 crossref_primary_10_1097_CMR_0b013e32835ae915 crossref_primary_10_4103_fjs_fjs_107_18 crossref_primary_10_2310_7750_2013_13045 crossref_primary_10_1038_s41582_020_0391_x crossref_primary_10_1002_jso_23574 crossref_primary_10_1007_s11912_013_0335_3 crossref_primary_10_1080_08923973_2023_2215403 crossref_primary_10_1016_j_ejca_2021_07_028 crossref_primary_10_1016_j_rpor_2015_12_001 crossref_primary_10_1093_neuonc_nos113 crossref_primary_10_1155_2012_294735 crossref_primary_10_1002_cncr_34435 crossref_primary_10_2217_mmt_15_16 crossref_primary_10_1016_j_hoc_2024_05_008 crossref_primary_10_3390_app14062222 crossref_primary_10_1093_noajnl_vdab170 crossref_primary_10_3389_fonc_2021_554668 crossref_primary_10_1007_s40495_016_0072_z crossref_primary_10_1007_s11060_016_2072_6 crossref_primary_10_1002_cam4_1223 crossref_primary_10_1007_s11912_011_0203_y crossref_primary_10_1007_s40257_022_00678_z crossref_primary_10_2478_raon_2022_0032 crossref_primary_10_1590_0101_60830000000118 crossref_primary_10_3389_fonc_2022_868004 crossref_primary_10_1016_j_clon_2013_07_002 crossref_primary_10_1007_s11095_018_2455_9 crossref_primary_10_3390_cancers15215263 crossref_primary_10_1097_CMR_0000000000000429 crossref_primary_10_1097_CMR_0b013e32834d3d88 crossref_primary_10_1016_j_ejca_2013_11_002 crossref_primary_10_1126_scitranslmed_ade8732 crossref_primary_10_1007_s11912_011_0200_1 crossref_primary_10_1007_s00761_013_2528_7 crossref_primary_10_1159_000461576 crossref_primary_10_3390_cancers12061635 crossref_primary_10_1016_j_clineuro_2013_03_019 crossref_primary_10_3390_cancers16122272 crossref_primary_10_1007_s00432_013_1553_7 crossref_primary_10_18632_oncotarget_19223 crossref_primary_10_3389_fonc_2022_824511 crossref_primary_10_3892_ijo_2015_2970 crossref_primary_10_1097_CMR_0000000000000338 crossref_primary_10_1111_cup_12746 crossref_primary_10_1111_pcmr_12771 crossref_primary_10_1186_s12885_015_1927_0 crossref_primary_10_1007_s12094_021_02607_8 crossref_primary_10_1097_CMR_0000000000000538 crossref_primary_10_1097_CMR_0b013e328352dbef crossref_primary_10_1159_000519281 crossref_primary_10_1016_j_canrad_2014_11_001 crossref_primary_10_1097_CMR_0000000000000382 crossref_primary_10_1186_s12885_015_1517_1 crossref_primary_10_5301_jbm_5000089 |
Cites_doi | 10.1159/000076903 10.1007/BF02071520 10.1056/NEJMra072149 10.1016/S0360-3016(96)00619-0 10.1097/CMR.0b013e3283090031 10.1038/nature08021 10.1002/cncr.22868 10.1158/0008-5472.CAN-08-0041 10.6004/jnccn.2009.0020 10.1002/cncr.22905 10.1038/nm.2072 10.1200/JCO.2006.08.1463 10.1159/000070289 10.1200/JCO.2009.23.4799 10.1200/JCO.1993.11.4.638 10.1215/15228517-2007-058 10.1200/JCO.2004.08.140 10.3171/jns.1998.88.1.0011 10.1158/1078-0432.CCR-07-4139 10.1097/01.pas.0000213262.61855.7d |
ContentType | Journal Article |
Copyright | Copyright © 2010 American Cancer Society 2015 INIST-CNRS Copyright © 2010 American Cancer Society. |
Copyright_xml | – notice: Copyright © 2010 American Cancer Society – notice: 2015 INIST-CNRS – notice: Copyright © 2010 American Cancer Society. |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7TK 7X8 |
DOI | 10.1002/cncr.25643 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Neurosciences Abstracts MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Neurosciences Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE Neurosciences Abstracts MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1097-0142 |
EndPage | 1720 |
ExternalDocumentID | 10_1002_cncr_25643 21472718 24042181 CNCR25643 |
Genre | article Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: 5 P30 CA 016087-27 – fundername: NCI NIH HHS grantid: P30 CA016087-28 – fundername: NCI NIH HHS grantid: P30 CA016087-29 – fundername: NCI NIH HHS grantid: P30 CA016087 |
GroupedDBID | --- -~X .3N .GA .Y3 05W 0R~ 10A 1CY 1L6 1OC 24P 29B 31~ 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5VS 66C 6J9 6P2 6PF 702 7PT 8-0 8-1 8-3 8-4 8-5 85S 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AARRQ AAWTL AAXRX AAZKR ABCQN ABCUV ABEML ABHFT ABIJN ABIVO ABJNI ABLJU ABOCM ABPPZ ABPVW ABQWH ABXGK ACAHQ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACNCT ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEIGN AEIMD AENEX AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFZJQ AGNAY AHBTC AIACR AIAGR AITYG AIURR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BAWUL BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM E3Z EBS EJD EX3 F00 F01 F04 F5P FD6 FUBAC G-S G.N GNP GODZA GX1 H.X HBH HF~ HGLYW HHY HHZ HZ~ IH2 IX1 J0M JPC KBYEO KQQ KZ1 L7B LATKE LAW LC2 LC3 LH4 LITHE LMP LOXES LP6 LP7 LSO LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 QRW R.K ROL RWI RX1 RYL SJN SUPJJ TEORI UDS UHB V2E V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WJL WOHZO WQJ WRC WVDHM WXI WXSBR XG1 XPP XV2 Z0Y ZGI ZZTAW ~IA ~WT .GJ 08R 3O- AAJUZ AAUGY AAVGM ABCVL ABHUG ABPTK ABWRO ACCFJ ACXME ADAWD ADDAD AEEZP AEQDE AFFNX AFVGU AGJLS AI. AIWBW AJBDE AKALU C1A EMOBN H~9 IQODW J5H N4W NEJ OHT RSU VH1 WHG XFK Y6R YQJ ZA5 ZXP CGR CUY CVF ECM EIF NPM AAMNL AAYXX CITATION 7TK 7X8 |
ID | FETCH-LOGICAL-c4273-d7160f7f891df3a93016371404452ea4ddfdffd4c48eee64e457cfca28879ca83 |
IEDL.DBID | 33P |
ISSN | 0008-543X 1097-0142 |
IngestDate | Fri Aug 16 07:55:19 EDT 2024 Fri Aug 16 23:58:09 EDT 2024 Thu Nov 21 21:20:36 EST 2024 Sat Sep 28 07:59:13 EDT 2024 Sun Oct 22 16:05:35 EDT 2023 Sat Aug 24 01:04:39 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Keywords | Nervous system diseases Prognosis Brain cancer Central nervous system melanoma Tumorigenicity Malignant tumor Cerebral metastasis brain Carcinogenesis Survival Cerebral disorder Encephalon metastases Cancerology outcomes Central nervous system disease Malignant melanoma Primary Ulceration Cancer |
Language | English |
License | CC BY 4.0 Copyright © 2010 American Cancer Society. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4273-d7160f7f891df3a93016371404452ea4ddfdffd4c48eee64e457cfca28879ca83 |
Notes | Preliminary findings were presented at the Annual Meeting of the American Society of Clinical Oncology; May 29‐June 2, 2009; Orlando, FL. See editorial and companion articles on pages 1560‐3, 1687‐96, and 1697‐703, this issue. The first 2 authors contributed equally to this article. Fax: (212) 263‐9090 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.25643 |
PMID | 21472718 |
PQID | 1238123040 |
PQPubID | 23462 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_861204081 proquest_miscellaneous_1238123040 crossref_primary_10_1002_cncr_25643 pubmed_primary_21472718 pascalfrancis_primary_24042181 wiley_primary_10_1002_cncr_25643_CNCR25643 |
PublicationCentury | 2000 |
PublicationDate | 15 April 2011 |
PublicationDateYYYYMMDD | 2011-04-15 |
PublicationDate_xml | – month: 04 year: 2011 text: 15 April 2011 day: 15 |
PublicationDecade | 2010 |
PublicationPlace | Hoboken |
PublicationPlace_xml | – name: Hoboken – name: Hoboken, NJ – name: United States |
PublicationTitle | Cancer |
PublicationTitleAlternate | Cancer |
PublicationYear | 2011 |
Publisher | Wiley Subscription Services, Inc., A Wiley Company Wiley-Blackwell |
Publisher_xml | – name: Wiley Subscription Services, Inc., A Wiley Company – name: Wiley-Blackwell |
References | 2004; 22 2006; 30 2010; 16 2004; 27 2008; 18 2008; 14 2008; 10 2004 1992; 16 2009; 459 2009; 27 1998; 88 2007; 357 1984; 53 2007; 215 1997; 37 2007; 110 1993; 11 2005; 52 2008; 68 2007; 60 2009; 7 2009; 1 2003; 64 2007; 25 18765540 - Clin Cancer Res. 2008 Sep 1;14(17):5484-93 17623835 - Cancer. 2007 Sep 15;110(6):1329-37 18046031 - N Engl J Med. 2007 Nov 29;357(22):2277-84 19966936 - Am J Transl Res. 2009;1(1):35-43 18626311 - Melanoma Res. 2008 Aug;18(4):268-73 19917835 - J Clin Oncol. 2009 Dec 20;27(36):6199-206 15800714 - Neoplasma. 2005;52(2):150-8 8478659 - J Clin Oncol. 1993 Apr;11(4):638-43 17369575 - J Clin Oncol. 2007 Mar 20;25(9):1129-34 19401060 - J Natl Compr Canc Netw. 2009 Mar;7(3):250-75 6713349 - Cancer. 1984 Jun 1;53(11):2550-2 15138346 - Onkologie. 2004 Apr;27(2):145-9 18559492 - Cancer Res. 2008 Jun 15;68(12):4500-5 15051777 - J Clin Oncol. 2004 Apr 1;22(7):1293-300 12759528 - Oncology. 2003;64(4):328-35 17620286 - Cancer. 2007 Sep 1;110(5):1107-14 9128946 - Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51 17063079 - Am J Surg Pathol. 2006 Nov;30(11):1396-400 19421193 - Nature. 2009 Jun 18;459(7249):1005-9 17587834 - Dermatology. 2007;215(1):10-6 18287337 - Neuro Oncol. 2008 Apr;10(2):199-207 20023634 - Nat Med. 2010 Jan;16(1):116-22 1561798 - World J Surg. 1992 Mar-Apr;16(2):191-5 21472703 - Cancer. 2011 Apr 15;117(8):1560-3 17327791 - Neurosurgery. 2007 Mar;60(3):471-81; discussion 481-2 9420067 - J Neurosurg. 1998 Jan;88(1):11-20 e_1_2_7_5_2 e_1_2_7_4_2 e_1_2_7_3_2 e_1_2_7_2_2 Mathieu D (e_1_2_7_22_2) 2007; 60 e_1_2_7_8_2 Eggermont AM (e_1_2_7_12_2) 2009; 27 e_1_2_7_7_2 e_1_2_7_18_2 Baurain J (e_1_2_7_13_2) 2009; 27 e_1_2_7_17_2 e_1_2_7_16_2 Madajewicz S (e_1_2_7_20_2) 1984; 53 e_1_2_7_15_2 e_1_2_7_11_2 e_1_2_7_10_2 Panagiotou IE (e_1_2_7_19_2) 2005; 52 e_1_2_7_26_2 e_1_2_7_27_2 e_1_2_7_28_2 e_1_2_7_29_2 Thompson JF (e_1_2_7_6_2) 2004 Hofmann MA (e_1_2_7_9_2) 2007; 215 e_1_2_7_25_2 Wich LG (e_1_2_7_14_2) 2009; 1 e_1_2_7_24_2 e_1_2_7_23_2 e_1_2_7_21_2 |
References_xml | – volume: 53 start-page: 2550 year: 1984 end-page: 2552 article-title: Malignant melanoma brain metastases publication-title: Review of Roswell Park Memorial Institute experience. Cancer. – volume: 110 start-page: 1329 year: 2007 end-page: 1337 article-title: Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases publication-title: Cancer. – volume: 18 start-page: 268 year: 2008 end-page: 273 article-title: Serum matrix metalloproteinase‐8 is associated with ulceration and vascular invasion of malignant melanoma publication-title: Melanoma Res. – volume: 68 start-page: 4500 year: 2008 end-page: 4505 article-title: Development of a preclinical model of spontaneous human melanoma central nervous system metastasis publication-title: Cancer Res. – volume: 88 start-page: 11 year: 1998 end-page: 20 article-title: Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma publication-title: J Neurosurg. – volume: 27 start-page: 145 year: 2004 end-page: 149 article-title: Survival and prognostic factors in patients with brain metastases from malignant melanoma publication-title: Onkologie. – volume: 27 issue: 15 suppl year: 2009 article-title: Association of primary melanoma ulceration and clinical benefit of adjuvant vaccination with tumor‐specific antigen peptides [abstract] publication-title: J Clin Oncol. – volume: 25 start-page: 1129 year: 2007 end-page: 1134 article-title: Identification of high‐risk patients among those diagnosed with thin cutaneous melanomas publication-title: J Clin Oncol. – volume: 64 start-page: 328 year: 2003 end-page: 335 article-title: Biochemotherapy for metastatic melanoma with limited central nervous system involvement publication-title: Oncology. – volume: 52 start-page: 150 year: 2005 end-page: 158 article-title: Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome publication-title: Neoplasma. – volume: 1 start-page: 35 year: 2009 end-page: 43 article-title: Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research publication-title: Am J Transl Res. – volume: 27 start-page: 6199 year: 2009 end-page: 6206 article-title: Final version of 2009 AJCC melanoma staging and classification publication-title: J Clin Oncol. – volume: 30 start-page: 1396 year: 2006 end-page: 1400 article-title: Prognostic significance of extent of ulceration in primary cutaneous melanoma publication-title: Am J Surg Pathol. – volume: 16 start-page: 191 year: 1992 end-page: 195 article-title: Predicting survival and recurrence in localized melanoma: a multivariate approach publication-title: World J Surg. – volume: 27 issue: 15 suppl year: 2009 publication-title: J Clin Oncol. – volume: 11 start-page: 638 year: 1993 end-page: 643 article-title: Role of computed tomography in the staging of primary melanoma publication-title: J Clin Oncol. – volume: 357 start-page: 2277 year: 2007 end-page: 2284 article-title: Computed tomography–an increasing source of radiation exposure publication-title: N Engl J Med. – volume: 14 start-page: 5484 year: 2008 end-page: 5493 article-title: Effective CpG immunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis publication-title: Clin Cancer Res. – volume: 37 start-page: 745 year: 1997 end-page: 751 article-title: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials publication-title: Int J Radiat Oncol Biol Phys. – volume: 110 start-page: 1107 year: 2007 end-page: 1114 article-title: Role of radiologic imaging at the time of initial diagnosis of stage T1b‐T3b melanoma publication-title: Cancer. – year: 2004 – volume: 22 start-page: 1293 year: 2004 end-page: 1300 article-title: Determinants of outcome in melanoma patients with cerebral metastases publication-title: J Clin Oncol. – volume: 60 start-page: 471 year: 2007 end-page: 481 article-title: et al publication-title: Gamma knife radiosurgery in the management of malignant melanoma brain metastases. – volume: 7 start-page: 250 year: 2009 end-page: 275 article-title: Melanoma publication-title: J Natl Compr Canc Netw. – volume: 16 start-page: 116 year: 2010 end-page: 122 article-title: Real‐time imaging reveals the single steps of brain metastasis formation publication-title: Nat Med. – volume: 10 start-page: 199 year: 2008 end-page: 207 article-title: Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features publication-title: Neuro Oncol. – volume: 215 start-page: 10 year: 2007 end-page: 16 article-title: et al publication-title: Prognostic factors and impact of treatment in melanoma brain metastases: better prognosis for women? Dermatology. – volume: 459 start-page: 1005 year: 2009 end-page: 1009 article-title: Genes that mediate breast cancer metastasis to the brain publication-title: Nature. – volume: 215 start-page: 10 year: 2007 ident: e_1_2_7_9_2 article-title: et al publication-title: Prognostic factors and impact of treatment in melanoma brain metastases: better prognosis for women? Dermatology. contributor: fullname: Hofmann MA – ident: e_1_2_7_4_2 doi: 10.1159/000076903 – ident: e_1_2_7_17_2 doi: 10.1007/BF02071520 – ident: e_1_2_7_27_2 doi: 10.1056/NEJMra072149 – volume-title: Textbook of Melanoma year: 2004 ident: e_1_2_7_6_2 contributor: fullname: Thompson JF – ident: e_1_2_7_5_2 doi: 10.1016/S0360-3016(96)00619-0 – ident: e_1_2_7_15_2 doi: 10.1097/CMR.0b013e3283090031 – volume: 27 issue: 15 year: 2009 ident: e_1_2_7_13_2 article-title: Association of primary melanoma ulceration and clinical benefit of adjuvant vaccination with tumor‐specific antigen peptides [abstract] publication-title: J Clin Oncol. contributor: fullname: Baurain J – volume: 53 start-page: 2550 year: 1984 ident: e_1_2_7_20_2 article-title: Malignant melanoma brain metastases publication-title: Review of Roswell Park Memorial Institute experience. Cancer. contributor: fullname: Madajewicz S – ident: e_1_2_7_18_2 doi: 10.1038/nature08021 – ident: e_1_2_7_25_2 doi: 10.1002/cncr.22868 – volume: 52 start-page: 150 year: 2005 ident: e_1_2_7_19_2 article-title: Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome publication-title: Neoplasma. contributor: fullname: Panagiotou IE – ident: e_1_2_7_7_2 doi: 10.1158/0008-5472.CAN-08-0041 – ident: e_1_2_7_24_2 doi: 10.6004/jnccn.2009.0020 – ident: e_1_2_7_21_2 doi: 10.1002/cncr.22905 – ident: e_1_2_7_28_2 doi: 10.1038/nm.2072 – ident: e_1_2_7_11_2 doi: 10.1200/JCO.2006.08.1463 – ident: e_1_2_7_23_2 doi: 10.1159/000070289 – ident: e_1_2_7_10_2 doi: 10.1200/JCO.2009.23.4799 – volume: 60 start-page: 471 year: 2007 ident: e_1_2_7_22_2 article-title: et al publication-title: Gamma knife radiosurgery in the management of malignant melanoma brain metastases. contributor: fullname: Mathieu D – ident: e_1_2_7_26_2 doi: 10.1200/JCO.1993.11.4.638 – ident: e_1_2_7_8_2 doi: 10.1215/15228517-2007-058 – ident: e_1_2_7_3_2 doi: 10.1200/JCO.2004.08.140 – ident: e_1_2_7_2_2 doi: 10.3171/jns.1998.88.1.0011 – volume: 27 issue: 15 year: 2009 ident: e_1_2_7_12_2 publication-title: J Clin Oncol. contributor: fullname: Eggermont AM – ident: e_1_2_7_29_2 doi: 10.1158/1078-0432.CCR-07-4139 – volume: 1 start-page: 35 year: 2009 ident: e_1_2_7_14_2 article-title: Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research publication-title: Am J Transl Res. contributor: fullname: Wich LG – ident: e_1_2_7_16_2 doi: 10.1097/01.pas.0000213262.61855.7d |
SSID | ssj0007253 |
Score | 2.3881578 |
Snippet | BACKGROUND:
Melanoma patients who develop brain metastases (B‐Met) have limited survival and are excluded from most clinical trials. In the current study, the... Melanoma patients who develop brain metastases (B-Met) have limited survival and are excluded from most clinical trials. In the current study, the authors... BACKGROUND: Melanoma patients who develop brain metastases (B-Met) have limited survival and are excluded from most clinical trials. In the current study, the... BACKGROUNDMelanoma patients who develop brain metastases (B-Met) have limited survival and are excluded from most clinical trials. In the current study, the... |
SourceID | proquest crossref pubmed pascalfrancis wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1711 |
SubjectTerms | Age Factors Aged Biological and medical sciences Brain Brain Neoplasms - mortality Brain Neoplasms - pathology Brain Neoplasms - secondary Cancer Clinical trials Dermatology Female Head and neck Humans Male Medical sciences Melanoma Melanoma - mortality Melanoma - pathology Melanoma - secondary Metastases Middle Aged Multivariate analysis outcomes Prognosis Regression analysis Skin Neoplasms - pathology Survival Survival Analysis Tumors Tumors of the skin and soft tissue. Premalignant lesions ulceration |
Title | Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post‐brain metastases survival |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcncr.25643 https://www.ncbi.nlm.nih.gov/pubmed/21472718 https://search.proquest.com/docview/1238123040 https://search.proquest.com/docview/861204081 |
Volume | 117 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEB7aHEqhJH3XTRNU2lPBjR-jtQy5hE1CLw2lD8jNyHqcsnZYr3PuT-ghvzC_pDOyd5elaSH0ZluyLDSvbyTrE8B7LAudqJrSEo0uRiyyWEufxxSsmPtDok7CIbbfirNzdXzCNDmHy70wAz_EasKNLSP4azZwXXcHa9JQ05j5RwrYyFSflCaE_Rv5l5UbLrKRgjJRscT8fMVNmh2sX92IRo8udUcD44cTLW6DnJsINoSg053_6_xj2B6hpzgadOUJ3HPNU3jweVxcfwbXI0fohbiiBJq3VHVCN1ZcDoQUYtHP2rkwmwzPVMoNsNMUrRcEJ4Vd_4fEj2buQjftTIuaT6Og24UmRNotG2-7xc3PX3-UdT35MLKC5_Dj9OT79FM8HtoQGyQoFFtKwBJfeFWm1ue6ZJEHVkBEmTmN1nrrvUWDyjk3QYeyMN7ojLxdabTKX8BW0zbuFQjJRDJuoimIavTGqrrMbOkmRVorlNJF8G4pvGocimpgYc4qHuAqDHAE-xtyXVUlLIMMcCJ4uxR0RbbFCya6cW3fVSnjGZ41TyIQf6mjCCJSBW7m5aAk6w-kpPoU-yP4EHThH52spmfTr-Hq9V0q78LDYY4b41S-ga3FvHd7cL-z_X4wht87BQ-m |
link.rule.ids | 315,782,786,1408,27933,27934,46064,46488 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Jb9QwFH6iRYJKFWuXsBQjOCGlzfI8cQ4c0NCqiHaEoEi9RR4vp05STSY99yf00F_IL-G9JDOjEYuEuCWx41h-2-fn-DPAW8wzHakxTUs0uhAxS0ItfRpSsGLuD4k6ag-x_ZaNztXHQ6bJeT_fC9PxQywSbmwZrb9mA-eE9MGSNdSUZrpPERvTNbiLA9JE3sGRflk44izpSSgjFUpMzxfspMnB8t2VeLR5qWsaGt-dafE70LmKYdsgdPTwP7v_CB706FN86NTlMdxx5RO4d9qvrz-F254m9EJc0Ryad1XVQpdWXHacFGLWTKqpMKskz1TKDbDfFJUXhCiFXf6KxI8m7kKX1USLMR9IQbczTaC0njde1bMf1ze_lNUNuTEyhC34fnR4NjwO-3MbQoOEhkJLc7DIZ17lsfWpzlnqLTEgokycRmu99d6iQeWcG6BDmRlvdEIOLzdapduwXlal2wUhmUvGDTTFUY3eWDXOE5u7QRaPFUrpAngzl17RD0XRETEnBQ9w0Q5wAHsrgl1UJTiDjHECeD2XdEHmxWsmunRVUxcxQxpOnEcBiD_UUYQSqQI3s9NpyfIDMWk_hf8A3rXK8JdOFsPR8Gt79exfKr-C-8dnpyfFyafR5-ew0aW8MYzlC1ifTRv3EtZq2-y1lvETQtETzg |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RIlWVEI-2QHgUV3CqlDaP8caRuKBtVyBgVQGVeou8fpy6yWqz4cxP4MAv5Jcwk2R3tQIqIW5JPHGsGc_MZzv-DPAK80xHakLDEo0uRMySUEufhpSsmPtDoo7aQ2w_Z-MrdXbONDmvl3thOn6I1YQbe0Ybr9nBZ9afrklDTWnmJ5SwMd2C20g4nJnz0_RiFYezpOegjFQoMb1akZMmp-t3N9LRnZmuSTO-O9LiT5hzE8K2OWh07_9afx_u9thTvOk6ywO45co92PnYr67vw4-eJPRafKURNO-pqoUurZh1jBRi0UyruTCbFM9UyhVw1BSVF4QnhV3_iMSPpu5al9VUiwkfR0G3C02QtF5WXtWLn9--_1ZWNxTEyA0O4HJ0_mX4NuxPbQgNEhYKLY3AIp95lcfWpzpnm7e0gIgycRqt9dZ7iwaVc26ADmVmvNEJhbvcaJU-hO2yKt1jEJKZZNxAUxbV6I1VkzyxuRtk8UShlC6Al0vjFb0qio6GOSlYwUWr4AAON-y6EiUwg4xwAjhaGrog5-IVE126qqmLmAENT5tHAYi_yCjCiCTA1TzqOsn6AzH1fUr-ARy3feGGRhbD8fBTe_XkX4RfwM7F2aj48G78_insdvPdGMbyGWwv5o17Dlu1bQ5bv_gF58oSdA |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+variables+and+primary+tumor+characteristics+predictive+of+the+development+of+melanoma+brain+metastases+and+post%E2%80%90brain+metastases+survival&rft.jtitle=Cancer&rft.au=Zakrzewski%2C+Jan&rft.au=Geraghty%2C+Laurel+N.&rft.au=Rose%2C+Amy+E.&rft.au=Christos%2C+Paul+J.&rft.date=2011-04-15&rft.pub=Wiley+Subscription+Services%2C+Inc.%2C+A+Wiley+Company&rft.issn=0008-543X&rft.eissn=1097-0142&rft.volume=117&rft.issue=8&rft.spage=1711&rft.epage=1720&rft_id=info:doi/10.1002%2Fcncr.25643&rft.externalDBID=10.1002%252Fcncr.25643&rft.externalDocID=CNCR25643 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-543X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-543X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-543X&client=summon |